Pages that link to "Q86032588"

The following pages link to The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients (Q86032588):

Displaying 16 items.

• The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies (Q26744317) (← links)
• Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. (Q30235846) (← links)
• Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial (Q36990093) (← links)
• Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials (Q37696496) (← links)
• Effects of GLP-1 in the kidney (Q38208950) (← links)
• Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes (Q38261573) (← links)
• Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks. (Q39290337) (← links)
• Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats (Q41811427) (← links)
• Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors (Q48131140) (← links)
• GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes (Q50225916) (← links)
• Diabetic nephropathy: newer therapeutic perspectives (Q58712499) (← links)
• Two cases of advanced stage rapidly progressive diabetic nephropathy effectively treated with combination therapy including RAS blocker, GLP-1 receptor agonist and SGLT-2 inhibitor (Q64299445) (← links)
• Low-density lipoprotein apheresis ameliorates monthly estimated glomerular filtration rate declines in patients with renal cholesterol crystal embolism (Q85903454) (← links)
• Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial (Q89128962) (← links)
• Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression (Q90439858) (← links)
• Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects (Q91984454) (← links)